These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells. Failly M; Korur S; Egler V; Boulay JL; Lino MM; Imber R; Merlo A Mol Cancer Ther; 2007 Feb; 6(2):773-81. PubMed ID: 17308073 [TBL] [Abstract][Full Text] [Related]
26. New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies. El-Sayed NA; Nour MS; Salem MA; Arafa RK Eur J Med Chem; 2019 Dec; 183():111693. PubMed ID: 31539778 [TBL] [Abstract][Full Text] [Related]
27. Strong Anti-tumorous Potential of Nardostachys jatamansi Rhizome Extract on Glioblastoma and In Silico Analysis of its Molecular Drug Targets. Kapoor H; Yadav N; Chopra M; Mahapatra SC; Agrawal V Curr Cancer Drug Targets; 2017; 17(1):74-88. PubMed ID: 27774879 [TBL] [Abstract][Full Text] [Related]
28. PRMT5 as a druggable target for glioblastoma therapy. Banasavadi-Siddegowda YK; Welker AM; An M; Yang X; Zhou W; Shi G; Imitola J; Li C; Hsu S; Wang J; Phelps M; Zhang J; Beattie CE; Baiocchi R; Kaur B Neuro Oncol; 2018 May; 20(6):753-763. PubMed ID: 29106602 [TBL] [Abstract][Full Text] [Related]
29. MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells. Yacoub A; Mitchell C; Hong Y; Gopalkrishnan RV; Su ZZ; Gupta P; Sauane M; Lebedeva IV; Curiel DT; Mahasreshti PJ; Rosenfeld MR; Broaddus WC; James CD; Grant S; Fisher PB; Dent P Cancer Biol Ther; 2004 Aug; 3(8):739-51. PubMed ID: 15197348 [TBL] [Abstract][Full Text] [Related]
30. Promising potential of boron compounds against Glioblastoma: In Vitro antioxidant, anti-inflammatory and anticancer studies. Turkez H; Arslan ME; Tatar A; Mardinoglu A Neurochem Int; 2021 Oct; 149():105137. PubMed ID: 34293392 [TBL] [Abstract][Full Text] [Related]
31. Caffeine suppresses the progression of human glioblastoma via cathepsin B and MAPK signaling pathway. Cheng YC; Ding YM; Hueng DY; Chen JY; Chen Y J Nutr Biochem; 2016 Jul; 33():63-72. PubMed ID: 27260469 [TBL] [Abstract][Full Text] [Related]
32. A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma. Guo G; Gong K; Ali S; Ali N; Shallwani S; Hatanpaa KJ; Pan E; Mickey B; Burma S; Wang DH; Kesari S; Sarkaria JN; Zhao D; Habib AA Nat Neurosci; 2017 Aug; 20(8):1074-1084. PubMed ID: 28604685 [TBL] [Abstract][Full Text] [Related]
33. In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines. Avramis IA; Christodoulopoulos G; Suzuki A; Laug WE; Gonzalez-Gomez I; McNamara G; Sausville EA; Avramis VI Cancer Chemother Pharmacol; 2002 Dec; 50(6):479-89. PubMed ID: 12451475 [TBL] [Abstract][Full Text] [Related]
34. Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma. Ashizawa T; Miyata H; Iizuka A; Komiyama M; Oshita C; Kume A; Nogami M; Yagoto M; Ito I; Oishi T; Watanabe R; Mitsuya K; Matsuno K; Furuya T; Okawara T; Otsuka M; Ogo N; Asai A; Nakasu Y; Yamaguchi K; Akiyama Y Int J Oncol; 2013 Jul; 43(1):219-27. PubMed ID: 23612755 [TBL] [Abstract][Full Text] [Related]
35. Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cells. Premkumar DR; Jane EP; Pollack IF Cancer Biol Ther; 2015; 16(2):233-43. PubMed ID: 25482928 [TBL] [Abstract][Full Text] [Related]
36. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition. Maher M; Kassab AE; Zaher AF; Mahmoud Z Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080 [TBL] [Abstract][Full Text] [Related]
37. Helianthin induces antiproliferative effect on human glioblastoma cells in vitro. Alexandru O; Dragutescu L; Tataranu L; Ciubotaru V; Sevastre A; Georgescu AM; Purcaru O; Danoiu S; Bäcklund LM; Dricu A J Neurooncol; 2011 Mar; 102(1):9-18. PubMed ID: 20635119 [TBL] [Abstract][Full Text] [Related]
38. Case-specific potentiation of glioblastoma drugs by pterostilbene. Schmidt L; Baskaran S; Johansson P; Padhan N; Matuszewski D; Green LC; Elfineh L; Wee S; Häggblad M; Martens U; Westermark B; Forsberg-Nilsson K; Uhrbom L; Claesson-Welsh L; Andäng M; Sintorn IM; Lundgren B; Lönnstedt I; Krona C; Nelander S Oncotarget; 2016 Nov; 7(45):73200-73215. PubMed ID: 27689322 [TBL] [Abstract][Full Text] [Related]
39. 6-MOMIPP, a novel brain-penetrant anti-mitotic indolyl-chalcone, inhibits glioblastoma growth and viability. Du S; Sarver JG; Trabbic CJ; Erhardt PW; Schroering A; Maltese WA Cancer Chemother Pharmacol; 2019 Feb; 83(2):237-254. PubMed ID: 30426158 [TBL] [Abstract][Full Text] [Related]
40. Discovery of novel pyruvate dehydrogenase kinases inhibitors by screening of an in-house small molecule library for anti-lung cancer therapeutics. Guo F; Zhao S; Li X Bioorg Med Chem Lett; 2019 Jan; 29(2):291-296. PubMed ID: 30470491 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]